Skip to main content

Semantic Decision-Making Corrupted in MCI, AD


Patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) are consistently slower and less accurate than healthy control persons in making semantic decisions in response to stimuli with words and images, new research shows.
Brady Kirchberg and colleagues at Hofstra North Shore–Long Island Jewish School of Medicine, Manhasset, New York, found that both MCI and AD groups were not only less accurate and slower than healthy control participants in making semantic decisions in response to word stimuli but also that the deficit worsened as the sizes of the objects being compared became more similar.
When line drawings were used as stimuli, the size of the drawings themselves had an undue influence upon semantic knowledge judgments in the 2 groups, investigators add.
Performance on the semantic distance task was also a "strong and significant" predictor of everyday functional capacity.
Dr. Terry Goldberg
"When MCI/AD patients have to make decisions about the size of real-world objects, they are less accurate than controls, and that gets amplified when they have to make fine-grained decisions about the size of these things in the real world," Terry Goldberg, PhD, who was the principle investigator of the study, toldMedscape Medical News.
"So making these size distinctions becomes increasingly more difficult for patients with MCI and AD, and we think it's because semantic knowledge gets corrupted with advancing disease, especially disease in the temporal lobe."
The study was published in the December issue of the American Journal of Psychiatry.
Semantic Processing
For the study, investigators studied semantic processing in 25 patients with amnestic MCI; 27 with mild to moderate AD; and 70 healthy control participants.
To do so, they used a novel paradigm that does not require overt word retrieval but rather capitalizes on "distance effects" in the semantic system.
Semantic memory was then assessed using a semantic distance task in which participants had to judge which of 2 entities, presented as images or words, was larger in the real world.
Semantic distance was also manipulated by adjusting the disparity in real-world size between the 2 entities that were being compared.
Images were also presented either as "congruent," in which the image of the larger real-world object was larger than the image of the smaller object, or "incongruent," in which the image of the smaller object was larger than the image of the larger object.
In addition to their main findings, investigators observed that the MCI/AD groups each had disproportionately more difficulty than control participants when making accurate responses in comparisons involving small semantic distances.
The same 2 groups were also disproportionately slower in making responses to contrasts involving small semantic distances.
Collapsing across image congruency conditions, the MCI/AD groups also demonstrated steeper declines in performance as they went from easier to harder small-distance conditions.
Across this task, performance declined 8 percentage points for healthy control participants, 11 percentage points for the MCI group, and 12 percentage points for the AD group.
Critically, investigators add, abnormalities in semantic processing were related to compromises in everyday functional competence as measured by the UCSD Performance-Based Skills Assessment tool.
"You could say these people had a word finding problem — they knew the answers, they just couldn't find the word, but this was nonverbal, so it's not that people can't come up with the word," Dr. Goldberg said.
"So this reflects loss of knowledge — they once had knowledge, but because of disease, the neurons become less functional, and they die. At the same time, we showed this kind of processing impairment compromises how a person does in terms of everyday function, so these problems impact on daily function for the worse."
The "Incongruent Condition"
In an accompanying editorial, David Salmon, PhD, University of California, San Diego, pointed out that the image effect observed between the 3 groups in the study was largely driven by the incongruent condition.
In the incongruent condition, "patients with mild cognitive impairment performed similarly to healthy subjects in tasks with large semantic distances and similarly to Alzheimer's disease patients in tasks with the more semantically demanding small distances."
Nevertheless, the deficits in semantic memory shown in this study "add confidence to the growing perception that subtle decline in this cognitive domain occurs in patient with amnestic mild cognitive impairment," Dr. Salmon observed.
He also suggested that decrements in semantic memory as seen in MCI patients in this study suggest that loss of semantic knowledge may be an important reason for this decline, insofar as early loss of semantic knowledge may contribute to a decline in judgment.
The study was funded by the Feinstein Institute for Medical Research and the Litwin-Zucker Center for Research in Alzheimer's Disease and Memory Disorders. Dr. Goldberg received an investigator-initiated grant from Pfizer/Eisai.

Comments

Popular posts from this blog

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...